Financial Performance - Operating revenue reached CNY 60,990,393.72, a 199.47% increase year-on-year[8] - Net profit attributable to shareholders was CNY 13,336,533.53, compared to a loss of CNY 5,333,030.55 in the same period last year[8] - Basic earnings per share improved to CNY 0.23 from a loss of CNY -0.11 in the same period last year[8] - Operating profit for Q1 2021 was ¥14,534,958.39, compared to a loss of ¥6,588,367.89 in Q1 2020, indicating a turnaround in profitability[30] - Net profit for Q1 2021 was ¥13,336,533.53, recovering from a net loss of ¥5,333,030.55 in Q1 2020[31] - The company achieved an investment income of ¥2,567,085.16 in Q1 2021, contributing positively to overall profitability[30] - In Q1 2021, the company reported a total comprehensive income of CNY 13,744,318.41, compared to a loss of CNY 556,761.11 in Q1 2020[34] Asset Growth - Total assets increased by 164.21% to CNY 783,139,544.11 compared to the end of the previous year[8] - As of March 31, 2021, total assets reached ¥783,139,544.11, a significant increase from ¥296,410,327.69 on December 31, 2020, reflecting a growth of approximately 164%[22] - Total current assets amounted to ¥608,679,217.30, compared to ¥158,654,487.72 at the end of 2020, indicating a growth of about 284%[22] - The company's total liabilities decreased to ¥66,949,934.56 from ¥90,023,007.92, representing a reduction of approximately 26%[23] - The total equity attributable to shareholders increased to ¥716,189,609.55 from ¥206,387,319.77, marking a growth of around 248%[24] - The total assets of the company amounted to ¥752,820,621.65 in Q1 2021, compared to ¥260,183,218.03 in Q4 2020, indicating substantial growth in asset base[28] Cash Flow and Financing - The net cash flow from operating activities was CNY 7,445,872.43, a significant recovery from a negative cash flow of CNY -10,450,769.74 in the previous year[8] - The company reported a cash inflow from financing activities of ¥479.47 million, a dramatic increase of 24,645.27% due to IPO fundraising[16] - The company raised CNY 518,890,428.41 from financing activities in Q1 2021, a substantial increase from CNY 20,000,000.00 in Q1 2020[37] - The net cash flow from financing activities was CNY 479,469,346.49 in Q1 2021, compared to CNY 1,937,620.40 in Q1 2020, showing a notable increase[37] - The ending cash and cash equivalents balance for Q1 2021 was CNY 506,416,822.95, a significant increase from CNY 77,883,684.47 in Q1 2020[37] Shareholder Information - The total number of shareholders reached 2,828 by the end of the reporting period[12] - The largest shareholder, Hai Rui Xiang Tian Biological Technology (Group) Co., Ltd., holds 55.66% of the shares[12] Research and Development - R&D expenditure as a percentage of operating revenue decreased to 10.67% from 26.78%[8] - Research and development expenses rose to ¥6.51 million, an increase of 19.35% from ¥5.45 million in the previous year, indicating ongoing investment in innovation[16] - Research and development expenses for Q1 2021 were ¥6,508,135.29, up from ¥5,453,130.12 in Q1 2020, highlighting continued investment in innovation[30] Liabilities and Debt Management - Long-term borrowings decreased by 84.53% to ¥3.71 million from ¥23.98 million, attributed to the replacement of loans with IPO funds[15] - The company’s total liabilities decreased to ¥36,859,018.34 in Q1 2021 from ¥54,431,689.38 in Q4 2020, reflecting improved financial health[28] - Total liabilities rose from CNY 90,023,007.92 to CNY 98,235,445.21, with current liabilities totaling CNY 63,227,410.59[43] - The company has a long-term loan of CNY 23,982,978.81, indicating a stable debt structure[43] Inventory and Receivables - Accounts receivable stood at ¥25,391,222.85, down from ¥29,898,529.29, showing a decrease of about 15%[22] - Inventory levels were reported at ¥60,631,082.80, slightly down from ¥61,947,687.01, indicating a decrease of approximately 2%[22] - Other receivables increased by 578.63% to ¥8.42 million, primarily due to interest accrual on idle fundraising deposits[15] Market and Product Development - The company did not report any new products or technologies in this quarter[49] - There were no updates on market expansion or mergers and acquisitions during the call[49]

Dividend and Profit Distribution - The company plans to distribute a cash dividend of RMB 3 per 10 shares, totaling approximately RMB 18.9175 million, which accounts for 33.41% of the net profit attributable to shareholders for 2020[5]. - The company has not proposed any other forms of profit distribution aside from cash dividends[5]. - The company’s profit distribution plan has been approved by the board and requires shareholder meeting approval[5]. Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB for the year, representing a growth of 25% compared to the previous year[12]. - In 2020, the company's operating revenue was CNY 221.86 million, a decrease of 14.38% compared to CNY 259.13 million in 2019[22]. - The net profit attributable to shareholders was CNY 56.62 million, down 11.31% from CNY 63.84 million in 2019[22]. - The net profit after deducting non-recurring gains and losses decreased by 29.99% to CNY 42.75 million[22]. - The company's total assets increased by 4.67% to CNY 296.41 million at the end of 2020[22]. - The net assets attributable to shareholders increased by 37.93% to CNY 206.39 million[22]. - The basic earnings per share were CNY 1.20, down 11.11% from CNY 1.35 in 2019[23]. Audit and Compliance - The company has received a standard unqualified audit report from Lixin Certified Public Accountants[5]. - The board of directors and supervisory board members have confirmed the authenticity, accuracy, and completeness of the annual report[5]. - The company has not violated decision-making procedures for external guarantees[7]. - There are no special arrangements for corporate governance noted in the report[8]. - The company has disclosed all related party transactions in accordance with legal and regulatory requirements, ensuring transparency[160]. - There are no undisclosed related party transactions that should have been reported under applicable laws and regulations[160]. Research and Development - Research and development efforts are focused on improving existing diagnostic technologies, with a budget allocation of 10% of total revenue for R&D activities[12]. - The total R&D investment for the year was CNY 24.13 million, a decrease of 5.14% from the previous year, while the R&D investment as a percentage of revenue increased to 10.88% from 9.82%[67]. - The company has obtained 131 product registration certificates, with 52 products receiving EU CE certification, and holds a total of 41 patents, including 19 invention patents[65]. - The company is currently developing a fully automated nanomagnetic chemiluminescence self-immune detection product, with a total expected investment of CNY 16.23 million[70]. Market Expansion and Strategy - The company is expanding its market presence by entering new regions, with plans to establish partnerships in Southeast Asia by the end of 2021[12]. - The company expects continued growth in the next fiscal year, projecting a revenue increase of 20% to 1.44 billion RMB[14]. - The company aims to enhance its product offerings in the autoimmune disease detection market, maintaining a competitive advantage with a rich menu of chemiluminescence products[71]. - The company plans to enhance its market share in the allergy testing field by expanding its product offerings and improving service quality[131]. Risks and Challenges - The company has outlined potential risks in the report, which investors should be aware of[6]. - The report includes a forward-looking statement risk declaration, indicating that future plans do not constitute a commitment to investors[6]. - The company faces risks related to the development and registration of new products, which typically require over one year for completion[88]. - The company is at risk of its enzyme-linked immunosorbent assay products being replaced by chemiluminescence products, which are becoming the mainstream diagnostic method[89]. Operational Efficiency - The implementation of the "two-invoice system" is expected to streamline operations and reduce costs, potentially increasing profit margins by 5%[13]. - The company employs a procurement model that emphasizes the stability of raw material quality, establishing long-term relationships with qualified suppliers[37]. - The production model is based on "sales-driven production," ensuring safety stock levels while responding to customer orders[39]. Corporate Governance - The actual controllers hold 67.92% of the voting rights, raising concerns about potential improper control[97]. - The actual controllers confirmed that their shares are legally held without any pledges or disputes[144]. - The company has committed to ensuring that the contents of the prospectus do not contain false records, misleading statements, or significant omissions, and will bear legal responsibility for the accuracy and completeness of the information provided[171]. Shareholder Commitments - The actual controller and shareholders committed to not transferring or entrusting the management of their shares for 36 months post-IPO[141]. - If the stock price falls below the IPO price for 20 consecutive trading days, the lock-up period will automatically extend by 6 months[142]. - The company will strictly adhere to regulations regarding share reduction after the lock-up period, ensuring stable operations[144]. Product Development and Innovation - New product launches include the "Nabok" brand, which utilizes advanced nanomagnetic chemiluminescence technology for autoimmune disease detection, enhancing sensitivity and speed[13]. - The company has developed core technologies in enzyme-linked immunoassay and chemiluminescence, achieving significant advancements in sensitivity and specificity[62]. - The company aims to replace high-priced imported enzyme-linked immunosorbent assay products with its own chemiluminescence products in the autoimmune detection field[36].